“Johnson & Johnson: Buy Rating Reaffirmed Despite Price Target Cut, Growth Prospects Highlighted”
Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Supply Chain9h
Podcast | How Healthcare Giant Johnson & Johnson Is Making Its Supply Chain Sustainable
How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...
Johnson & Johnson's SWOT analysis: oncology portfolio drives growth amid challenges
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.